2026 State Psychedelic Policy Tracker: 115 Bills, 17 Laws, and the Ibogaine Research Wave
State legislatures filed approximately 115 psychedelic-related bills in 2026, spanning 41 states and seven federal measures, according to data compiled by Psychedelic Alpha. Of these, roughly 17 were signed into law, two were vetoed, 44 died with their legislative sessions, and approximately 50 remained pending as of mid-year.
Ibogaine emerged as the defining policy theme. Roughly 25 bills across 14 states addressed the West African plant-derived compound, with six enacted into law. This state-level activity unfolded against a federal backdrop: an April 2026 White House executive order directed the FDA, HHS, and Department of Veterans Affairs to expand psychedelic trials, established a Right-to-Try pathway, designated veterans as a priority population, and allocated $50 million through ARPA-H to match state research investments.
The Ibogaine Wave
The 2026 legislative session marked a pivot toward ibogaine-specific research frameworks. Unlike broader psychedelic reform measures of prior years, these bills narrowly authorize clinical trials and institutional participation rather than decriminalization or regulated access.
Tennessee’s Helping Open Pathways to Effective (HOPE) Treatment Act (HB2075/SB2149), signed into law, permits state institutions to join a federally authorized multi-state ibogaine clinical trial consortium for PTSD and opioid-use disorder. The law creates a Council on Emerging Behavioral Health Treatments and an innovation fund, with applications opening by September 1, 2026. Notably, the statute requires no state appropriation and explicitly preserves ibogaine’s Schedule I status outside approved trials.
Colorado’s HB26-1325, enacted May 12, 2026, establishes a more elaborate structure: a first-in-nation ibogaine research pilot program within the Behavioral Health Administration, authorizing up to five research sites. The law takes effect August 12, 2026, but contains a contingent activation clause requiring $150,000 in gifts or grants be raised before January 1, 2028.
Colorado’s Indigenous Benefit-Sharing Precedent
HB26-1325 introduces a novel statutory requirement: research licensees must establish benefit-sharing plans with Indigenous communities connected to the iboga plant. This provision, effective upon the law’s activation, may suggest a template for addressing bioprospecting concerns in federally prohibited research areas. The requirement applies to institutional licensees rather than individual researchers, and the statute does not specify enforcement mechanisms or community selection criteria.
The Money Question: Opioid Settlement vs. Federal Match
Funding sources reveal divergent state strategies. Tennessee’s framework requires no direct state expenditure. Colorado’s pilot depends on private philanthropy. Michigan’s HB6020, by contrast, proposes redirecting $50 million from the Michigan Opioid Healing and Recovery Fund—derived from the state’s approximately $1.8 billion opioid settlement—into an ibogaine grant program at the Michigan Department of Health and Human Services.
The bill, heard by the House Families and Veterans Committee in June 2026, attracted bipartisan sponsorship but faced internal Democratic opposition over the use of settlement dollars for experimental interventions. No committee vote was scheduled as of the hearing date.
The White House’s April 2026 executive order complicates this landscape. The $50 million ARPA-H allocation is designated to match state research investments, separate from any Michigan appropriation. Researchers are exploring whether state opioid settlement funds would qualify for federal matching, a determination that may affect legislative calculus in pending bills.
MDMA for Veterans: Maryland’s Group Therapy Study
While ibogaine dominated legislative filings, MDMA research advanced through alternative pathways. Maryland’s PTSD & TBI Alternative Therapies Fund allocated $1 million—supplemented by $525,000 from the nonprofit Reason for Hope—to Sunstone Therapies for a study comparing group-based versus individual MDMA-assisted therapy for veterans with PTSD. Enrollment was scheduled to begin mid-June 2026.
This represents a funded study rather than statutory change; no bill was enacted. The VA concurrently launched an approximately 80-veteran MDMA trial, operating under federal research authorities independent of state legislation.
Law vs. Press Release
The 2026 landscape requires careful parsing of policy status. Colorado’s HB26-1325 and Tennessee’s HOPE Act are signed laws with effective dates and implementation timelines. Michigan’s HB6020 remains pending, having received only committee testimony. Maryland’s MDMA study is a funded research initiative without accompanying legislation. The White House executive order is administrative directive, not congressional appropriation.
Approximately 50 bills remained pending across states as of mid-2026, with outcomes contingent on session calendars, committee action, and gubernatorial disposition.
The 2026 state tracker (signed, pending, and funded)
| State | Measure | Status | What it does |
|---|---|---|---|
| Colorado | HB26-1325 | SIGNED LAW | Creates a first-in-nation ibogaine research pilot (up to 5 sites) inside the Behavioral Health Administration, and requires licensees to establish benefit-sharing plans with Indigenous communities connected to the iboga plant. Passed May 12, 2026; effective Aug 12, 2026; contingent on raising $150,000 in gifts/grants before Jan 1, 2028. |
| Tennessee | HOPE Act (HB2075 / SB2149) | SIGNED LAW | The Helping Open Pathways to Effective (HOPE) Treatment Act lets Tennessee institutions join a federally authorized multi-state ibogaine clinical-trial consortium for PTSD and opioid-use disorder. Creates a Council on Emerging Behavioral Health Treatments and an innovation fund; application window opens by Sept 1, 2026. Requires no state funding and does NOT legalize ibogaine outside approved trials (still Schedule I). |
| Michigan | HB6020 | PENDING (committee testimony only) | A bipartisan bill that would move $50 million from the Michigan Opioid Healing and Recovery Fund (part of the state’s ~$1.8B opioid settlement) into an ibogaine grant program at MDHHS, and let Michigan join the multi-state research consortium. Heard by the House Families and Veterans Committee in June 2026 (testimony only, no vote); some Democrats object to using settlement dollars for experimental trials. |
| Maryland | State-funded study (no new statute) | FUNDED STUDY | Maryland’s PTSD & TBI Alternative Therapies Fund put $1 million (plus $525,000 from Reason for Hope) toward a Sunstone Therapies study — the first to directly compare GROUP vs INDIVIDUAL MDMA-assisted therapy for veterans with PTSD. Enrollment begins mid-June 2026. |
Sources
- ¶Colorado General Assembly, HB26-1325 — https://leg.colorado.gov/bills/HB26-1325
- ¶Tennessee General Assembly / NewsChannel9 — https://newschannel9.com/news/local/tennessee-lawmakers-approve-hope-act-to-allow-ibogaine-clinical-trials-for-addiction
- ¶Michigan Advance — https://michiganadvance.com/2026/06/03/gop-bill-would-use-opioid-funds-to-jumpstart-clinical-trials-on-psychedelic-based-trauma-treatment/
- ¶Sunstone Therapies — https://www.sunstonetherapies.com/group-mdma-therapy-veterans-ptsd-study/
- ¶Psychedelic Alpha bill tracker — https://psychedelicalpha.com/data/psychedelic-bill-tracker
- ¶White House EO, ‘Accelerating Medical Treatments for Serious Mental Illness’ (April 2026)
Educational Disclaimer
This article is for informational and educational purposes only. It is not
medical advice, mental health advice, diagnosis, treatment guidance, or a
recommendation to use any substance, supplement, therapy, or protocol.
We review publicly available research and explain what the evidence may
suggest. Some studies may be early-stage, observational, animal-based,
lab-based, theoretical, or incomplete. Always consult a qualified
professional before making health-related decisions.
If you or someone you know is struggling, you are not alone. In the US, call or text 988 (Suicide & Crisis Lifeline). Elsewhere, contact your local emergency or crisis service.
Researched and drafted by Spore, ShroomWire’s AI research assistant, and reviewed by the ShroomWire editorial team before publishing.
